BIOMARKERS PODIUM PRESENTATIONS

Neuroimaging: Sex and ethnoracial differences – Biomarkers

Sex-associated differences in pathology burden in early-onset Alzheimer's disease

Jenna Rae Groh ¹ Eddie Stage Jr. ¹ Paige E. Logan ¹ Leonardo Iaccarino ²
Renaud Joie ³ Paul S Aisen ⁴ Ani Eloyan ⁵ Anne M. Fagan ⁶ Tatiana M. Foroud ¹
Constantine Gatsonis ⁷ Clifford R. Jack Jr. ⁸ Joel H. kramer ⁹ Robert A. Koeppe ¹⁰
Andrew J. Saykin ¹¹ Arthur W. Toga ¹² Prashanthi Vemuri ⁸ Gregory S. Day ¹³
Neill R. Graff-Radford ¹⁴ Lawrence S. Honig ¹⁵ David T. Jones ⁸
Joseph C. Masdeu ¹⁶ Mario F. Mendez ¹⁷ Chiadi U. Onyike ¹⁸ Emily J. Rogalski ¹⁹
Maria C. Carrillo ²⁰ Brad C. Dickerson ²¹ Liana G. Apostolova ¹¹

¹ Indiana University School of Medicine, Indianapolis, IN, USA

² University of California, San Francisco, San Francisco, CA, USA

³ Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA

⁴ Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

⁵ Brown University, Providence, RI, USA

⁶ Washington University School of Medicine, St. Louis, MO, USA

⁷ Dept. of Biostatistics, Brown University, Providence, RI, USA

⁸ Mayo Clinic, Rochester, MN, USA

⁹ UMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA

¹⁰ University of Michigan, Ann Arbor, MI, USA

¹¹ Indiana Alzheimer Disease Center, Indianapolis, IN, USA

¹² Laboratory of Neuro Imaging, Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

¹³ Mayo Clinic Florida, Jacksonville, FL, USA

¹⁴ Mayo Clinic, Jacksonville, FL, USA

Abstract

Background: Previous research has suggested that, compared to males, females are at greater risk for and have greater pathology burden in late onset. However, sex differences in early onset AD (EOAD) have not yet been studied.

Method: We included 167 participants [28 cognitively normal (CN, 68% females), 98 early onset AD (EOAD, 55% females), and 41 cognitively impaired amyloidnegative (EOnonAD, 31% females] subjects from the Longitudinal Early-Onset AD Study (LEADS) with available Flortaucipir PET, Florbetaben PET, and MRI data. Multiple linear regression (MLR) models including age and MMSE as covariates were used in the pooled sample to examine the effects of sex on hippocampal and white matter hyperintensity volume, mean cortical thickness, mean tau distribution by Braak regions and mean cortical amyloid SUVR. We also ran voxelwise MLR with sex as the predictor and cortical thickness, amyloid SUVR normalized to whole cerebellum, tau SUVR normalized to cerebellar crus, respectively, as the outcome measures while controlling for age, MMSE, and total intracranial volume (MRI only). Results are displayed at a cluster-level FWE correction of p<0.05.

Result: There were no significant demographic differences between males and females in any diagnostic group. Across the pooled sample females showed significantly greater atrophy of the hippocampus (p=0.0001), greater tau SUVR in Braak regions 3&4 (p=0.05) and 5&6 (p=0.04) and trend for greater global amyloid uptake (p=0.074) (Table 2). The analyses in imaging space confirmed these findings and showed that the effects are driven by the EOAD group. Females showed greater amyloid deposition globally and greater tau deposition in the frontal, inferior parietal and temporal lobes (Figure 3). ¹⁵ Columbia University Medical Center, New

York, NY, USA

¹⁶ Houston Methodist Neurological Institute, Houston, TX, USA

¹⁷ David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

¹⁸ Johns Hopkins University, Baltimore, MD, USA

¹⁹ Northwestern University, Chicago, IL, USA

²⁰ Alzheimer's Association, Chicago, IL, USA

 $^{\rm 21}$ Massachusetts General Hospital, Boston, MA, USA

Correspondence

Jenna Rae Groh, Indiana University School of Medicine, Indianapolis, IN, USA. Email: jengroh@iu.edu **Conclusion:** Female sex is associated with greater pathology burden in EOAD. Longitudinal studies will be needed to establish whether such difference translates in faster rates of progression in women relative to men.



Figure 1: Structural MRI measure by sex

FIGURE 1

TABLE 1

	CN	EOAD	EO non-AD		
N	62	99	39		
Age	54.4 (6.12)	58.8 (3.82)	57.3 (-6.42)		
Sex (M/F)	20/42	44/55	27/12		
Education (yrs)	16.8 (2.17)	15.5 (2.46)	15.6 (-2.6)		
MMSE	29.3 (0.75)	21.7 (4.99)	25.8 (-3.15)		
CDR Global (<0.5/ >=0.5)	40/0	1/60	0/14		
FBB SUVR	1.00 (0.05)	1.55 (0.17)	0.98 (-0.06)		

Table 1: Demographic comparisons



Figure 2: Amyloid and tau PET SUVR measures by sex

FIGURE 2

Figure 3: Voxelwise multiple linear regression models



FIGURE 3

THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION

TABLE 2

Table 2: Multiple linear regression models

	Model 1: Age	Model 2: Age, MMSE	Model 3: Age, Dx
MTL	0.0007 (0.980)	-0.013 (0.613)	0.006 (0.833)
Entorhinal cortex	0.006 (0.899)	-0.017 (0.674)	0.015 (0.718)
Hippocampal volume	289.6 (<.0001)	251.5 (0.0001)	320.8 (<.0001)
Mean Cortical Thickness	-0.012 (0.493)	-0.022 (0.114)	-0.012 (0.421)
WMH volume	239.7 (0.383)	320.6 (0.235)	66.77 (0.810)
BRAAK12	-0.019 (0.628)	0.009 (0.786)	-0.012 (0.675)
BRAAK34	-0.151 (0.018)	-0.087 (0.049)	-0.150 (0.0006)
BRAAK56	-0.168 (0.015)	-0.101 (0.040)	-0.164 (0.0007)
Mean Cortical Amyloid SUVR	-0.095 (0.030)	-0.065 (0.074)	-0.075 (<.0001)